Prescription Drug News and Research

RSS

State roundup: Mass. to allow coupons for some branded drugs

Johns Hopkins Hospital lost its coveted spot as the nation's top-ranked hospital for the first time in 22 years, edged out by Boston's Massachusetts General Hospital in the latest analysis by U.S. News & World Report to be released Tuesday. Hopkins still ranked No. 2, and marketing experts said falling one spot will hurt the hospital's ego more than its reputation.

18 Jul 2012

Drug coverage issues, dual eligibles program draw Democrats' interest

According to these stories from Politico and Politico Pro, some House Democrats are calling on the Department Of Health and Human Services to use the Medicare prescription drug program as a model for the health law's essential health benefits drug coverage requirement.

18 Jul 2012

First Edition: July 18, 2012

Today's headlines include coverage of a new report that offers a gloomy fiscal forecast for states as they confront rising health care costs, underfunded pensions and a range of other economic challenges.

18 Jul 2012

Healthier levels of vitamin C can reduce inflammatory conditions

The recommended dietary allowance, or RDA, of vitamin C is less than half what it should be, scientists argue in a recent report, because medical experts insist on evaluating this natural, but critical nutrient in the same way they do pharmaceutical drugs and reach faulty conclusions as a result.

17 Jul 2012

BioControl Medical receives FDA approval to initiate second phase of CardioFit study for heart failure

BioControl Medical has announced U.S. Food and Drug Administration approval to begin the second phase of INOVATE-HF (INcrease Of VAgal TonE in Heart Failure), a global, multi-center, investigational device exemption (IDE) clinical study of the company's CardioFit system for heart failure.

12 Jul 2012

FDA acknowledges receipt of resubmission of Human Genome Sciences’ raxibacumab BLA

Human Genome Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the resubmission of the Biologics License Application (BLA) for raxibacumab, a treatment for inhalational anthrax, and has established December 15, 2012 as the Prescription Drug User Fee Act (PDUFA) action date.

10 Jul 2012

FDA approves risk evaluation and mitigation strategy for ER and LA opioids

The U.S. Food and Drug Administration today approved a risk evaluation and mitigation strategy (REMS) for extended-release (ER) and long-acting (LA) opioids, highly potent drugs approved for moderate to severe, persistent pain that requires treatment for an extended period.

10 Jul 2012

AtheroNova receives U.S. patent allowance for 'Dissolution of Arterial Plaque'

AtheroNova Inc., a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, announced that it has received a Notice of Allowance for its patent application for Dissolution of Arterial Plaque.

10 Jul 2012

Humana acquires national chronic-care provider, SeniorBridge

Humana Inc. announced today it has completed its acquisition of SeniorBridge, a national chronic-care provider best known for providing in-home care management and caregiving services for seniors.

9 Jul 2012

NADDI lauds real-time, drug stop-sale system in North Carolina

The National Association of Drug Diversion Investigators (NADDI) – a nonprofit organization that facilitates cooperation between law enforcement, healthcare professionals, state regulatory agencies and pharmaceutical manufacturers in the prevention and investigation of drug diversion – today lauded the latest results achieved by the real-time, stop-sale system in North Carolina.

9 Jul 2012

JRD receives FDA priority review designation for XARELTO sNDAs to treat PE, DVT

Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental New Drug Applications (sNDAs) filed on May 2, 2012 for XARELTO (rivaroxaban), an oral anticoagulant, seeking new indications to treat patients with deep vein thrombosis (DVT), pulmonary embolism (PE), and to prevent recurrent DVT and PE.

9 Jul 2012

Prescription drug warning labels fail to capture patients' attention

Many patients seem to ignore prescription drug warning labels with instructions that are critical for safe and effective use, according to a study by a Kansas State University researcher working with scientists at Michigan State University.

6 Jul 2012

FDA action affects companies that manufacture and distribute unapproved oxycodone drugs

The U.S. Food and Drug Administration today issued a Federal Register notice instructing companies to stop manufacturing and distributing certain unapproved drugs that contain oxycodone. The notice is part of the FDA's Unapproved Drugs Initiative to remove unapproved new drugs from the market.

6 Jul 2012

Antidepressant use among seniors: Falling through Medicare's doughnut hole?

A new study links the gap in Medicare Part D coverage and cutbacks by seniors in using this and other medications.

4 Jul 2012

First Edition: July 3, 2012

Today's headlines include reports that continue to delve into the policy-oriented and political repercussions of last week's high court decision on the health law.

3 Jul 2012

FDA accepts BLA filing and grants Priority Review to ThromboGenics' ocriplasmin

ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that it has officially accepted the filing of the Biologics License Application for ocriplasmin intravitreal injection, 2.5 mg/ml and granted it Priority Review.

3 Jul 2012

Catalyst Health Solutions, SXC complete merger

SXC Health Solutions Corp., a leading provider of pharmacy benefit management (PBM) services and healthcare information technology (HCIT) solutions to the healthcare benefits management industry, announces that it has completed its previously disclosed merger of Catalyst Health Solutions, Inc. with a wholly-owned subsidiary of SXC.

3 Jul 2012

Onyx commences ENDEAVOR Kyprolis Phase 3 trial for relapsed multiple myeloma

Onyx Pharmaceuticals, Inc. announced today that the company has begun enrollment in the ENDEAVOR trial, a Phase 3 trial evaluating Kyprolis in combination with dexamethasone, versus bortezomib with dexamethasone in patients with relapsed multiple myeloma.

2 Jul 2012

Study tracks changes in spending, prices, and use of health care services by children

Spending on health care for children grew faster than spending for adults between 2007 and 2010 due to increasing prices for all categories of goods and services, finds a new report from the Health Care Cost Institute (HCCI).

2 Jul 2012

Rutgers explains significance of Supreme Court upholding the health care law

The Supreme Court upheld the core of President Obama's health care overhaul, ruling that the government can require all Americans to obtain health insurance or pay a penalty.

2 Jul 2012